Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Akari Therapeutics, Plc (AKTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4673-0.0015 (-0.32%)
At close: 03:58PM EST
0.4900 +0.02 (+4.86%)
After hours: 04:24PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.4688
Open0.4775
Bid0.4601 x 1400
Ask0.5000 x 1000
Day's Range0.4550 - 0.4775
52 Week Range0.3800 - 1.6100
Volume28,381
Avg. Volume76,135
Market Cap34.79M
Beta (5Y Monthly)1.43
PE Ratio (TTM)N/A
EPS (TTM)-0.5410
Earnings DateDec 07, 2022 - Dec 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Akari Therapeutics to Present at Biotech Showcase™ 2023

    NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET. The presentation will include progress highlights from Akari’s two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a nove

  • GlobeNewswire

    Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

    NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will participate in the investor-focused Cantor Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference taking place in Miami December 7-8, 2022. Akari President and CEO Rachelle Jacques will take part in an ophthalmology panel on December 8 a

  • GlobeNewswire

    Akari Therapeutics to Participate in the Ophthalmology Day at BTIG

    NEW YORK and LONDON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Ophthalmology Day at BTIG on November 29, 2022. President and CEO Rachelle Jacques will participate in a fireside chat scheduled for 9:30 am ET. Akari will be discussing progress in the development of long-acting PAS-nomacopan in geographic

Advertisement
Advertisement